Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin degludec/liraglutide (IDegLira) is a novel combination of insulin degludec (IDeg) and liraglutide. This trial investigated the contribution of the liraglutide component of IDegLira versus IDeg alone on efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5–10.0% [58–86 mmol/mol]) on basal insulin (20–40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma glucose between 4 and 5 mmol/L. Maximum allowed doses were 50 dose steps (equal to 50 units IDeg plus 1.8 mg liraglutide) and 50 units for IDeg. The primary end point was change in A1C from baseline. RESULTS: A total of 413 patients were randomized (mean A1C 8.8% [73 mmol/mol]; BMI 33.7 kg/m2). IDeg dose, alone or as part of IDegLira, was equivalent (45 units). A1C decreased by 1.9% (21 mmol/mol) with IDegLira and by 0.9% (10 mmol/mol) with IDeg (estimated treatment difference −1.1% [95% CI −1.3, −0.8], −12 mmol/mol [95% CI −14, −9; P < 0.0001). Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001. Hypoglycemia incidence was comparable (24% for IDegLira vs. 25% for IDeg). Overall adverse events were similar, and incidence of nausea was low in both groups (IDegLira 6.5% vs. IDeg 3.5%). CONCLUSIONS: IDegLira achieved glycemic control superior to that of IDeg at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss. These findings establish the efficacy and safety of IDegLira and the distinct contribution of the liraglutide component.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationWorld Medical Association Declaration of Helsinki
(2003) · Psychopharmacology · doi:10.1002/047086947x.oth1 · Cited by 1,332
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Inzucchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Peters, A., Tsapas, A., Wender, R., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc13-er02 · Cited by 805
Self-citationPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 1×
“IDegLira combines the complementary effects of IDeg and liraglutide on glycemic control (10,11,12).”
BackgroundSelf-citationGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366 · cited 1×
“IDeg in patients with type 2 diabetes inadequately controlled on metformin with or without pioglitazone supports the benefits of IDegLira compared with IDeg as well as liraglutide (21).”
BackgroundSelf-citation
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“In another 26-wk double-blind trial, 413 T2DM patients not controlled with basal insulin and metformin were randomly assigned to exchange basal insulin with insulin degludec or insulin degludec plus liraglutide; all patients continued metformin [192] .”
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“superior glycemic control over insulin degludec or liraglutide alone with benefits on weight loss when compared to insulin degludec [79,80].”
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care · doi:10.2337/dc19-0898 · Cited by 300
Self-citationAmbery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
“Both components offer substantial HbA1c-lowering; the GLP1RA component counteracts the weight gain that frequently accompanies insulin therapy (64, 65).”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“Both IDegLira and iGlarLixi have also been studied in patients with type 2 diabetes not adequately controlled on basal insulin.(78,81,83) Treatment intensification with IDegLira versus uptitration of basal insulin was evaluated over 26 weeks in the DUAL program.”
BackgroundMethodResultBody Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O’Neil, P. M. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 239
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Lingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220
Self-citationAddressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
Okemah, J., Peng, J., & Quiñones, M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0819-5 · Cited by 211
Billings, L. K., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H. W., Tentolouris, N., Grøn, R., Halladin, N., & Jodar, E. (2018) · Diabetes Care · doi:10.2337/dc17-1114 · Cited by 193
Self-citationGarvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Kempf, K., Altpeter, B., Berger, J., Reuß, O., Fuchs, M., Schneider, M., Gärtner, B., Niedermeier, K., & Martin, S. (2017) · Diabetes Care · doi:10.2337/dc17-0303 · Cited by 159
One hundred years of insulin therapy
Mathieu, C., Martens, P.-J., & Vangoitsenhoven, R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00542-w · Cited by 164
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 153
“T2DM Basal-Oral Therapy Seven RWD studies [32–38] and 10 RCTs [23, 39–47] reported hypoglycemia event rates in people with insulin-treated T2DM receiving basal-oral regimens (Table 2; Supplementary Table II).”
BackgroundPozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12937 · Cited by 137
“Similar results were observed with once daily lixisenatide or once weekly albiglutide [12, 13] and with fixed-combinations of insulin degludec and liraglutide or glargine and lixisenatide [14, 15].”
ResultLinjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0218-3 · Cited by 136
“higher [14] compared with other IDegLira trials where concomitant sulfonylurea treatment was not part of the background OAD therapy [11, 13].”
BackgroundResult2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 149
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 139
Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., & the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators (2016) · Diabetic Medicine · doi:10.1111/dme.13256 · Cited by 116
Self-citationNew forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Zinman, B., Marso, S. P., Christiansen, E., Calanna, S., Rasmussen, S., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dc17-2677 · Cited by 113
Self-citationLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 109
“The combination of insulin degludec and liraglutide (IDegLira) plus metformin was superior to Ideg plus metformin in achieving glycemic control and body weight reduction [71].”
BackgroundNon-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 101
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110
Huthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Guja, C., Frías, J. P., Somogyi, A., Jabbour, S. A., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 83
“Furthermore, fixed-ratio combinations of IG plus lixisenatide (iGlarLixi) and insulin degludec plus liraglutide (IDegLira) significantly decrease HbA1c and body weight, compared with their respective basal insulin monocomponents, without increasing hypoglycaemia risk.(24,25) Fixed-ratio combinations may not be suitabl…”
BackgroundMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Clinical use of insulin degludec
Vora, J. P., Cariou, B., Evans, M., Gross, J. L., Harris, S. B., Landstedt‐Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 84
Price, H. C., Blüher, M., Prager, R., Phan, T., Thorsted, B. L., Schultes, B., & for the EXTRA study group (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13182 · Cited by 71
“In clinical trials, IDegLira is weight-neutral in patients uncontrolled on OADs,(16,17,20) whereas it is associated with weight gain in patients uncontrolled on GLP-1RAs,(19) and weight loss in patients uncontrolled on basal insulin therapy.(15,18) Similar trends are observed in this real-world study, with the greates…”
ResultPhilis‐Tsimikas, A., Billings, L. K., Busch, R. S., Morales, C., Sahay, R. K., Halladin, N., Eggert, S., Begtrup, K., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13666 · Cited by 79
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Harris, S. B., Kocsis, G., Prager, R., Ridge, T., Chandarana, K., Halladin, N., & Jabbour, S. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12892 · Cited by 67
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundKalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 70
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Owens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 57
“Furthermore, a greater proportion of patients achieved glycaemic targets without weight gain or hypoglycaemia with IDegLira (36%) compared with insulin degludec alone (14%).(52) In DUAL-II, patients with T2DM previously treated with basal insulin plus metformin sulphonylureas/glinides, IDegLira achieved superior glyca…”
BackgroundResultInfluentialBasal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 57
Basal Insulin Use With GLP-1 Receptor Agonists
Anderson, S. L., & Trujillo, J. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.152 · Cited by 58
“Basal insulin (e.g., detemir, glargine, or degludec) is a recommended option at many stages of type 2 diabetes and is often added to oral antidiabetic agents (OADs) to achieve target fasting plasma glucose (FPG) levels.”
BackgroundInfluentialGlucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S., & Rendell, M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 55
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Perreault, L., Rodbard, H. W., Valentine, V., & Johnson, E. L. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0868-9 · Cited by 49
Self-citationTherapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“Also, insulin degludec in combination with liraglutide (IdegLira) is being developed for the treatment of patients with T2DM as once-daily administration and has proved superior to insulin degludec alone at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss [110].”
BackgroundGLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Lavernia, F., Adkins, S. E., & Shubrook, J. H. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1085293 · Cited by 47
“An FDC injectable containing ultra–long-acting basal insulin (degludec) and a GLP-1 receptor agonist (liraglutide) demonstrated good efficacy and safety [93-95], and was recently given marketing approval in the European Union [96].”
BackgroundKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Moreira, R. O., Cobas, R. A., & Coelho, R. C. L. A. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0327-4 · Cited by 46
“Insulin treated patients The DUAL-2 trial [25] was a 26-week, double-blind phase 3 trial, designed to confirm the superiority of IDegLira compared to insulin degludec alone.”
MethodAndreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Self-citationTreatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“Compared with the two components separately, IDegLira decreases HbA1c significantly more.[127,128]”
MethodShah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 44
Cohen, C. M., Chodick, G., Naftelberg, S., Shehadeh, N., & Karasik, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00725-9 · Cited by 39
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
Rodbard, H. W., Buse, J. B., Woo, V. C., Vilsbøll, T., Langbakke, I. H., Kvist, K., & Gough, S. C. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12574 · Cited by 36
“(C) Baseline characteristics in DUAL II [11].”
MethodInfluentialSelf-citationValentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 37
“Liraglutide reduces both FPG and PPG excursions [17] via its glucose-dependent effects on b- and a-cell function [17].”
BackgroundInfluentialMaiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.009 · Cited by 36
Watada, H., Kaneko, S., Komatsu, M., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Nakamura, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13859 · Cited by 37
“The safety and efficacy of IDegLira has been investigated in a number of patient populations in the global DUAL clinical trial programme, including the global DUAL II study which confirmed the superiority of IDegLira over degludec alone in terms of glycaemic control and established the contribution of the liraglutide…”
BackgroundResultInfluentialA review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
Nuffer, W. A., Guesnier, A., & Trujillo, J. M. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817752315 · Cited by 36
Ericsson, Å., & Lundqvist, A. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0301-y · Cited by 37
“Data from DUAL II [28] were used for baseline values for the model (Table 2).”
MethodBlonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Mathieu, C., Giorgino, F., Kim, S. G., Larsen, J. S., Philis‐Tsimikas, A., Ramachandran, A., da Rocha, T. J. C. M., Shankarappa, V. B., Terauchi, Y., & Ji, L. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00096-8 · Cited by 33
Davies, M. J., Glah, D. R., Chubb, B., Konidaris, G., & McEwan, P. C. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0433-9 · Cited by 31
Freemantle, N., Mamdani, M., Vilsbøll, T., Kongsø, J. H., Kvist, K., & Bain, S. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0142-y · Cited by 30
“DUAL II enrolled patients who had not achieved control on basal insulin therapy [15].”
InfluentialSelf-citationYoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 31
Wysham, C., Bonadonna, R. C., Aroda, V. R., Puig‐Domingo, M., Kapitza, C., Stager, W., Yu, C. H., Niemoeller, E., Souhami, E., Bergenstal, R. M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12961 · Cited by 31
“found additional benefit of the combination over basal insulin alone.(11,12)”
BackgroundCombining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
“However, we did review three additional randomized controlled trials [16, 22, 30].”
BackgroundMethodEvans, M., Billings, L. K., Håkan‐Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1409228 · Cited by 30
Peralta, F. G., Al‐Ozairi, E., Jude, E. B., Li, X., & Rosenstock, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14365 · Cited by 29
“nal adverse events were observed with IDegLira than with Lira, and weight changes from baseline significantly favoured IDegLira compared with basal insulin therapy.(36,37)”
ResultWysham, C. H., Lin, J., & Kuritzky, L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1297669 · Cited by 26
Kaku, K., Araki, E., Tanizawa, Y., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Inagaki, N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13856 · Cited by 32
“There were significantly fewer severe or blood glucose-confirmed hypoglycaemic episodes with IDegLira compared with degludec, reinforcing the contribution of the liraglutide component of IDegLira to the lower rate of hypoglycaemia seen with IDegLira in comparison with degludec in previous trials.(26) There was a signi…”
BackgroundResultKapitza, C., Bode, B. W., Ingwersen, S. H., Jacobsen, L. V., & Poulsen, P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.549 · Cited by 28
“8mg).(3,4) IDeg is a new-generation basal insulin with an ultralong duration of action, providing a flat and stable glucose-lowering effect.”
BackgroundMethodInfluentialYang, W., Cai, X., Gao, X., Chen, Y., Chen, L., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12764 · Cited by 29
King, A. B., Philis‐Tsimikas, A., Kilpatrick, E. S., Langbakke, I. H., Begtrup, K., & Vilsbøll, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0405 · Cited by 28
“This is consistent with the previously reported finding that IDegLira reduced the mean nine-point profile significantly more than liraglutide, but conferred a similar reduction to IDeg.15 The present analysis of the nine-point profiles also showed that treatment with IDegLira results in more patients achieving prepran…”
MethodResultInfluentialSelf-citationCai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
“Eight randomized clinical trials were included in the analysis (14-21), among which 3 trials were included with IIGlarLixi treatment (14-16) and 5 trials with IDegLira treatment compared with placebo or GLP-1RA alone or basal insulin alone (17-21).”
MethodYu, P., Agner, B. F. R., Luo, B., Dong, X., Li, D., Liu, J., Liu, L., Liu, M. R., Lu, Y., Nishida, T., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14522 · Cited by 34
“IDegLira was similarly confirmed to be superior in regard to the rate of severe or BG-confirmed hypoglycaemia versus degludec, in line with the trend reported in the global DUAL II trial.(12) Fear of hypoglycaemia is commonly identified by both people with diabetes and clinicians as a significant contributor to treatm…”
BackgroundResultInfluentialEldor, R., Avraham, N., Rosenberg, O., Shpigelman, M., Golan‐Cohen, A., Cukierman‐Yaffe, T., Merzon, E., & Buch, A. (2025) · Diabetes Care · doi:10.2337/dc25-0690 · Cited by 30
Alexopoulos, A., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 27
“In the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) II trial [26], 413 patients on basal insulin and metformin (±sulfonylurea or glinides) were randomized to once-daily insulin degludec/liraglutide+metformin or once-daily degludec+metformin in a blinded fashion.”
BackgroundSelf-citationNatale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Abdi, H., Azizi, F., & Amouzegar, A. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.65600 · Cited by 24
“compared GLP-1 agonists alone or as titratable fixed-ratio plus basal insulin with other injectable treatments (92); 26 RCTs (76-84) (86-88, 93-106), lasting 12 to 52 weeks and involving 11,425 patients were in-”
BackgroundMeier, J. J., Menge, B. A., Schenker, N., Erdmann, S., Kahle, M., Schliess, F., Kapitza, C., & Nauck, M. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13935 · Cited by 27
Liakopoulou, P., Liakos, A., Vasilakou, D., Athanasiadou, E. A., Bekiari, E., Kazakos, K., & Τσάπας, Α. (2017) · Endocrine · doi:10.1007/s12020-017-1293-6 · Cited by 25
Sofrà, D. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0234-y · Cited by 23
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Hunt, B., Mocarski, M., Valentine, W. J., & Langer, J. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1301943 · Cited by 24
Lisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
“DUAL II (46) NCT01392573 (2014) Individually randomized parallelgroup, doubleblind T2D; HbA1c 8.”
BackgroundRoussel, R., Durán-Garcia, S., Zhang, Y., Shah, S., Darmiento, C., Shankar, R. R., Golm, G. T., Lam, R. L. H., O’Neill, E. A., Gantz, I., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13574 · Cited by 21
“In studies that compared insulin degludec with a fixed ratio of insulin degludec + liraglutide, significant improvements in glycaemic control were observed.(26,27) In one of these studies,(26) in which the baseline HbA1c (72 – 73 mmol/mol [8.”
BackgroundHarris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 22
Self-citationPhysicians’ real-world experience with IDegLira: results of a European survey
Drummond, R. S., Baru, A., Dutkiewicz, M., Basse, A., & Tengmark, B.-O. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000531 · Cited by 21
“0%) within 6 months.(13) 14 16–19 It is important to note that respondents did not give the proportion of their patients achieving HbA1c <7% or their individual HbA1c targets.”
BackgroundMcGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 28
“Overall, studies have shown reductions in HbA1c in patients treated with FRC therapy compared with GLP-1 RA or non-insulin therapies [67–83], with less weight gain and reduced hypoglycemia compared with those treated with insulin alone [68, 70, 71, 73, 74, 77, 81, 82].”
ResultInsulin Degludec/Liraglutide: A Review in Type 2 Diabetes
Greig, S. L., & Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0448-0 · Cited by 20
“5–10 [17] or 7–9 % [18, 19], a body mass index (BMI) Insulin Degludec/Liraglutide: A Review 1525”
BackgroundMethodInfluentialIDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
Hunt, B., Mocarski, M., Valentine, W. J., & Langer, J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0251-x · Cited by 21
Giorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
“The combination was associated with superior glycemic control compared with insulin degludec [50].”
BackgroundWang, W., Agner, B. F. R., Luo, B., Liu, L., Liu, M. R., Peng, Y., Qu, S., Stachlewska, K., Wang, G., Yuan, G., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13286 · Cited by 26
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
Hughes, E. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2015.12.005 · Cited by 18
Metadata
- Authors
- Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- SSM Health Care (US)
- Texas Diabetes & Endocrinology (US)
- Novo Nordisk (Denmark) (DK)
- Endocrine and Metabolic Consultants, Clinical Research, Rockville, MD
- Corresponding author
- Buse, John B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-10
- Volume
- 37
- Issue
- 11
- Pages
- 2926-2933
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126862523
- Cited by
- 259
- References
- 27
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 10 · 2023: 11 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 30 · 2018: 39 · 2017: 41 · 2016: 30 · 2015: 26 · 2014: 4
- FWCI
- 26.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, liraglutide, IDegLira, type 2 diabetes, glycemic control, HbA1c, weight loss, hypoglycemia, basal insulin, metformin, GLP-1 receptor agonists, nausea, fixed-dose combination
- MeSH terms
- Liraglutide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Loss, Treatment Outcome, Insulin, Long-Acting, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.